RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Amplia Therapeutics Stock

Amplia Therapeutics P/S 2024

Amplia Therapeutics P/S

3.15

Ticker

ATX.AX

ISIN

AU0000023822

WKN

A2N5RL

As of Oct 2, 2024, Amplia Therapeutics's P/S ratio stood at 3.15, a -79.64% change from the 15.47 P/S ratio recorded in the previous year.

The Amplia Therapeutics P/S history

Amplia Therapeutics Aktienanalyse

What does Amplia Therapeutics do?

Amplia Therapeutics Ltd was originally founded in 2012 and is based in Sydney, Australia. The company focuses on the development of novel therapies for cancer and other serious diseases. Amplia's main focus is on the development of peptide-based therapeutics, which are polypeptides derived from naturally occurring proteins. The company also places special emphasis on non-coding RNA (ncRNA) research and is working on the discovery, development, and commercialization of drugs that specifically target ncRNA. Amplia already holds various patents and approvals in this field. Amplia's core business is the research and development of drugs for cancer. The company collaborates with academic research groups and institutions worldwide and works closely with manufacturers of synthetic peptides to ensure high quality and efficacy in drug production. Amplia has developed various drug platforms to support its research activities. One of these platforms is the peptide library, which contains a large collection of synthetic peptides that can be used against different types of cancer. Another platform is ncRNA-based therapeutics, which exert their effects by inhibiting ncRNA molecules. Currently, Amplia Therapeutics has several drugs in various stages of clinical development. One example is AMP945, a peptide designed as a potential medication for triple-negative breast cancer. The drug targets a protein receptor found on the surface of cancer cells and has shown promising results in inhibiting tumor growth in animal models. Another example is ATX101, an ncRNA inhibitor also being developed as a potential medication for cancer. The inhibitor targets a specific form of ncRNA molecule that is overproduced in various types of cancer. In animal models, the drug has shown promising results in preventing tumor progression. Overall, Amplia Therapeutics Ltd aims to develop drugs that can significantly improve the lives of patients. The company strives to set new standards in cancer therapy and continuously works to improve its technology platforms and expand its product pipeline. Amplia Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Amplia Therapeutics's P/S Ratio

Amplia Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Amplia Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Amplia Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Amplia Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Amplia Therapeutics stock

What is the price-to-earnings ratio of Amplia Therapeutics?

The price-earnings ratio of Amplia Therapeutics is currently 3.15.

How has the price-earnings ratio of Amplia Therapeutics changed compared to last year?

The price-to-earnings ratio of Amplia Therapeutics has increased by -79.64% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Amplia Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Amplia Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Amplia Therapeutics affect the company?

An increase in the price-earnings ratio of Amplia Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Amplia Therapeutics affect the company?

A decrease in the price-earnings ratio of Amplia Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Amplia Therapeutics?

Some factors that influence the price-earnings ratio of Amplia Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Amplia Therapeutics pay?

Over the past 12 months, Amplia Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amplia Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Amplia Therapeutics?

The current dividend yield of Amplia Therapeutics is .

When does Amplia Therapeutics pay dividends?

Amplia Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amplia Therapeutics?

Amplia Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Amplia Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amplia Therapeutics located?

Amplia Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amplia Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amplia Therapeutics from 10/2/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Amplia Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Amplia Therapeutics in the year 2023?

In the year 2023, Amplia Therapeutics distributed 0 AUD as dividends.

In which currency does Amplia Therapeutics pay out the dividend?

The dividends of Amplia Therapeutics are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Amplia Therapeutics

Our stock analysis for Amplia Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amplia Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.